• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023     National Institute for Health and Care Excellence (NICE) Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023     National Institute for Health and Care Excellence (NICE) Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023     National Institute for Health and Care Excellence (NICE) Devices for remote monitoring of Parkinson's disease. NICE diagnostics guidance 51
2023     WorkSafeBC Cryoneurolysis for shoulder pain
2023     Health Information and Quality Authority (HIQA) Health technology assessment of domiciliary invasive ventilation for adults with spinal cord injuries
2023     NIHR Health Services and Delivery Research programme Eye donation from palliative and hospice care contexts: the EDiPPPP mixed-methods study
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2023     National Institute for Health and Care Excellence (NICE) Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023     National Institute for Health and Care Excellence (NICE) Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023     National Institute for Health and Care Excellence (NICE) Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care. NICE diagnostics guidance 56
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lisocabtagene maraleucel (DLBCL, PMBCL and FL3B) - Benefit assessment according to §35a Social Code Book V]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effective analysis evaluation of galcanezumab (Emgality)]
2023     National Institute for Health and Care Excellence (NICE) Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023     National Institute for Health and Care Excellence (NICE) AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images. NICE diagnostics guidance 55
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonafarnib (Hutchinson-Gilford progeria syndrome or progeroid laminopathy) - Benefit assessment according to §35a SGB V [1], Sentence 11]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for etranacogene dezaparvovec acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     NIHR Health Technology Assessment programme Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bimekizumab (psoriatic arthritis) – Addendum to Commission A23-60]
2023     National Institute for Health and Care Excellence (NICE) Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023     National Institute for Health and Care Excellence (NICE) Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023     National Institute for Health and Care Excellence (NICE) FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care. NICE diagnostics guidance 48
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tezepelumab (severe asthma) - Benefit assessment according to § 35a SGB V]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Embolization vs. conservative management for spontaneous abdominal or pelvic hemorrhage
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66]
2023     National Institute for Health and Care Excellence (NICE) Mosunetuzumab for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 892
2023     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023     National Institute for Health and Care Excellence (NICE) Transperineal biopsy for diagnosing prostate cancer. NICE diagnostics guidance 54
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Review of the study protocol and statistical analysis plan on routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV) - Addendum to commission A21-130]
2023     NIHR Health Services and Delivery Research programme The effectiveness of sexual assault referral centres with regard to mental health and substance use: a national mixed-methods study – the MiMoS Study
2023     National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. NICE technology appraisal guidance 893
2023     National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023     National Institute for Health and Care Excellence (NICE) Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers. NICE diagnostics guidance 52
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lutetium vipivotide tetraxetan (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Canary Health Service [Software applications for prevention and intervention in people at risk of suicide: effectiveness, safety and cost-effectiveness]
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 894
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023     National Institute for Health and Care Excellence (NICE) MRI fusion biopsy systems for diagnosing prostate cancer. NICE diagnostics guidance 53
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V]
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. NICE technology appraisal guidance 895
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) MRI-based technologies for assessing non-alcoholic fatty liver disease. NICE diagnostics guidance 50
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Early intervention programs for adolescents and young adults with eating disorders
2023     National Institute for Health and Care Excellence (NICE) Bulevirtide for treating chronic hepatitis D. NICE technology appraisal guidance 896
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Spesolimab (generalized pustular psoriasis) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-sterile glove use
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pitolisant (narcolepsy, with or without cataplexy, children and adolescents, 6-17 years) – Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 897
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sotorasib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Somatropin for short stature
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonapegsomatropin (growth hormone deficiency) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 898
2023     National Institute for Health and Care Excellence (NICE) Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer. NICE interventional procedures guidance 763
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Direct-acting antivirals for pediatric chronic hepatitis C virus infection
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Talquetamab (multiple myeloma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). NICE technology appraisal guidance 899
2023     National Institute for Health and Care Excellence (NICE) Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries. NICE interventional procedures guidance 762
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Radiofrequency ablation for chronic knee, hip, and shoulder pain
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: innovations in home support, at the crossroads of humanity and technology]
2023     National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2023     National Institute for Health and Care Excellence (NICE) Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea. NICE interventional procedures guidance 760
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emicizumab (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Midline and extended dwell catheters for IV antibiotics
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sirolimus (Facial angiofibroma in tuberous sclerosis) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2023     National Institute for Health and Care Excellence (NICE) Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal). NICE technology appraisal guidance 901
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided biliary drainage for biliary obstruction. NICE interventional procedures guidance 761
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dapagliflozin (heart failure with preserved ejection fraction) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Semaglutide 2 mg for type 2 diabetes
2023     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 902
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases. NICE interventional procedures guidance 759
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Addendum to Commission A22-114]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) IV acetaminophen for acute pain in emergency departments
2023     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 903
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thoracic duct embolisation for persistent chyle leak. NICE interventional procedures guidance 755
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relugolix (prostate cancer) - Addendum to Commission A22-108]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Point of care ultrasound for guided central venous catheter insertion
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 904
2023     National Institute for Health and Care Excellence (NICE) Focal therapy using high-intensity focused ultrasound for localised prostate cancer. NICE interventional procedures guidance 756
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Anti–vascular endothelial growth factor drugs for age-related macular degeneration
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 905
2023     National Institute for Health and Care Excellence (NICE) Maximal cytoreductive surgery for advanced ovarian cancer. NICE interventional procedures guidance 757
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 2 and 3) - Benefit assessment according to §35a Social Code Book V]
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Case carts in surgical settings
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for preventing migraine. NICE technology appraisal guidance 906
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency ablation for palliation of painful spinal metastases. NICE interventional procedures guidance 758
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Endobronchial ultrasonography in malignant and benign pulmonary pathology: linear and radial ultrasound-guided transbronchial needle aspiration: evaluation of safety, efficacy, and cost-effectiveness]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Voclosporin (lupus nephritis) - Benefit assessment according to §35a Social Code Book V]
2023     Agency for Healthcare Research and Quality (AHRQ) Use of telehealth during the COVID-19 era
2023     Canadian Agency for Drugs and Technologies in Health (CADTH) Buprenorphine naloxone film versus tablets for opioid use disorder
2023     National Institute for Health and Care Excellence (NICE) Deucravacitinib for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 907
2023     National Institute for Health and Care Excellence (NICE) Endoluminal gastroplication for gastro-oesophageal reflux disease. NICE interventional procedures guidance 753